- Home
- PPBT vs CREV Comparison
PPBT vs CREV Comparison
Compare PPBT & CREV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- CREV
- Stock Information
- Founded
- PPBT 2010
- CREV 2007
- Country
- PPBT Israel
- CREV Ireland
- Employees
- PPBT N/A
- CREV N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- CREV
- Sector
- PPBT Health Care
- CREV
- Exchange
- PPBT Nasdaq
- CREV Nasdaq
- Market Cap
- PPBT 7.1M
- CREV 7.2M
- IPO Year
- PPBT N/A
- CREV N/A
- Fundamental
- Price
- PPBT $2.65
- CREV $2.78
- Analyst Decision
- PPBT Strong Buy
- CREV Strong Buy
- Analyst Count
- PPBT 1
- CREV 1
- Target Price
- PPBT $33.00
- CREV $39.00
- AVG Volume (30 Days)
- PPBT 12.3K
- CREV 14.1K
- Earning Date
- PPBT 03-10-2025
- CREV 01-01-0001
- Dividend Yield
- PPBT N/A
- CREV N/A
- EPS Growth
- PPBT N/A
- CREV N/A
- EPS
- PPBT N/A
- CREV N/A
- Revenue
- PPBT N/A
- CREV $39,261,077.00
- Revenue This Year
- PPBT N/A
- CREV $40.76
- Revenue Next Year
- PPBT N/A
- CREV $86.18
- P/E Ratio
- PPBT N/A
- CREV N/A
- Revenue Growth
- PPBT N/A
- CREV 41.52
- 52 Week Low
- PPBT $2.00
- CREV $2.00
- 52 Week High
- PPBT $20.60
- CREV $17.15
- Technical
- Relative Strength Index (RSI)
- PPBT 40.91
- CREV 40.96
- Support Level
- PPBT $2.64
- CREV $2.64
- Resistance Level
- PPBT $2.93
- CREV $3.31
- Average True Range (ATR)
- PPBT 0.15
- CREV 0.30
- MACD
- PPBT 0.02
- CREV 0.03
- Stochastic Oscillator
- PPBT 2.46
- CREV 17.28
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.